News UK blood cancer patients get early access to BMS drug Nivolumab made available ahead of EU approval in relapsed cHL.
News NICE finally recommends Eisai breast cancer drug after rethi... New trial evidence and price cut convinces NICE in reassessment.
Debates & Insight Sponsored Finding a cure: Getting the best Brexit deal for Britain’s l... Four months have now elapsed since the UK voted to leave the EU.
News Big pharma could leave UK - AZ's Pangalos Last week saw the publication of the UK's Accelerated Access Review, containing proposals to cut four years from the drug development process – but AstraZeneca seems unconvinced that access
News BMS' Opdivo still streets ahead of Merck rival BMS to refocus operations, according to Q3 results.
News AZ halts recruitment on head and neck cancer trial FDA calls for hold after reports of bleeding.
News EU clears first drug therapy for rare disease cALD Neuraxpharm and Minoryx' Nezglyal has become the first approved drug therapy in the EU for rare neurodegenerative disease cALD.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
